Published in Lancet on February 25, 1989
Abnormal cervical smear test results: old dilemmas and new directions. Br J Gen Pract (1992) 1.36
Risk targeting in cervical screening: a new look at an old problem. Br J Gen Pract (1992) 1.30
Rapid detection and typing of herpes simplex virus DNA in clinical specimens by the hybrid capture II signal amplification probe test. J Clin Microbiol (1997) 1.23
Demonstration of multiple HPV types in normal cervix and in cervical squamous cell carcinoma using the polymerase chain reaction on paraffin wax embedded material. J Clin Pathol (1990) 1.16
Development of type-specific and cross-reactive serological probes for the minor capsid protein of human papillomavirus type 33. J Virol (1993) 1.11
Lymphoproliferative response to fusion proteins of human papillomaviruses in patients with cervical intraepithelial neoplasia. Epidemiol Infect (1989) 0.87
Detection of human papillomavirus in matched cervical smears and biopsy specimens by non-isotopic in situ hybridisation. J Clin Pathol (1992) 0.86
Rapid viral diagnosis in perspective. BMJ (1990) 0.85
Invited commentary: Human papillomavirus infection and risk of cervical precancer--using the right methods to answer the right questions. Am J Epidemiol (2009) 0.81
Human papillomaviruses and cervical screening. Genitourin Med (1996) 0.78
Molecular techniques in the diagnosis of human infectious diseases. Genitourin Med (1990) 0.77
Detection of human papillomavirus in vulvar carcinoma. A study by in situ hybridisation. Arch Gynecol Obstet (1992) 0.76
Analysis of transforming gene regions of human papillomavirus type 16 in normal cervical smears. Arch Gynecol Obstet (1991) 0.75
Rapid viral diagnosis. BMJ (1990) 0.75
Human papillomaviruses and anal cancer. Genitourin Med (1989) 0.75
Detection of human papillomavirus 16 and 18 DNA in epithelial lesions of the lower genital tract by in situ hybridization and polymerase chain reaction: cervical scrapes are not substitutes for biopsies. J Clin Microbiol (1993) 0.75
Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer (1977) 53.23
Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol (1999) 40.46
DNA sequence and expression of the B95-8 Epstein-Barr virus genome. Nature (1984) 27.05
Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer (1976) 22.55
Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst (1995) 18.86
Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet (2003) 18.67
Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet (1998) 15.09
Floating absolute risk: an alternative to relative risk in survival and case-control analysis avoiding an arbitrary reference group. Stat Med (1991) 12.89
New human papovavirus (B.K.) isolated from urine after renal transplantation. Lancet (1971) 12.13
Patient participation in decision-making. Soc Sci Med (1998) 8.05
Cohort study analysis with a FORTRAN computer program. Int J Epidemiol (1986) 6.66
Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells. EMBO J (1987) 6.26
Phosphorylation of initiation factor elF-2 and the control of reticulocyte protein synthesis. Cell (1977) 6.22
Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst (1998) 6.06
Alcohol, tobacco and breast cancer--collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer (2002) 5.83
Collaborative United Kingdom-Australasian study of cancer in patients treated with immunosuppressive drugs. Br Med J (1979) 5.58
Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet (2000) 5.03
Assessment of the completeness and accuracy of computer medical records in four practices committed to recording data on computer. Br J Gen Pract (1995) 5.03
Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J (2001) 4.93
Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA (1999) 4.71
Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. JAMA (2001) 4.38
Cervical screening in an inner city area: response to a call system in general practice. BMJ (1988) 4.19
A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes. Br J Cancer (2002) 4.18
Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med (1999) 3.98
The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer (2008) 3.87
Clonal p53 mutation in primary cervical cancer: association with human-papillomavirus-negative tumours. Lancet (1992) 3.85
Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet (1995) 3.71
A spliced Epstein-Barr virus gene expressed in immortalized lymphocytes is created by circularization of the linear viral genome. EMBO J (1988) 3.69
Mesothelioma mortality in asbestos workers: implications for models of carcinogenesis and risk assessment. Br J Cancer (1982) 3.61
Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin Pharmacokinet (1999) 3.61
Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation. Cell (1991) 3.58
Accumulation of an mRNA and protein in interferon-treated Ehrlich ascites tumour cells. Nature (1979) 3.43
Early administration of oral oseltamivir increases the benefits of influenza treatment. J Antimicrob Chemother (2003) 3.24
Increasing body weight predicts the earlier onset of insulin-dependant diabetes in childhood: testing the 'accelerator hypothesis' (2). Diabet Med (2005) 3.21
Identification of human mononuclear leucocyte populations by esterase staining. Clin Exp Immunol (1977) 3.12
A promoter for the highly spliced EBNA family of RNAs of Epstein-Barr virus. J Virol (1987) 3.10
Restricted expression of EBV latent genes and T-lymphocyte-detected membrane antigen in Burkitt's lymphoma cells. EMBO J (1986) 3.07
The spliced BZLF1 gene of Epstein-Barr virus (EBV) transactivates an early EBV promoter and induces the virus productive cycle. J Virol (1989) 2.98
Complement activation by beta-amyloid in Alzheimer disease. Proc Natl Acad Sci U S A (1992) 2.84
Two related but differentially expressed potential membrane proteins encoded by the EcoRI Dhet region of Epstein-Barr virus B95-8. J Virol (1985) 2.82
The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050. Br J Cancer (2005) 2.81
EBNA-2 and EBNA-LP cooperate to cause G0 to G1 transition during immortalization of resting human B lymphocytes by Epstein-Barr virus. EMBO J (1994) 2.79
Management of traumatic intracranial haematoma. Br Med J (Clin Res Ed) (1982) 2.79
Transcription and DNA sequence of the BamHI L fragment of B95-8 Epstein-Barr virus. EMBO J (1984) 2.77
A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet (2000) 2.69
Long-term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail older population. J Am Geriatr Soc (2001) 2.67
Antibodies to human papillomavirus and to other genital infectious agents and invasive cervical cancer risk. Lancet (1993) 2.58
Trial of early nifedipine in acute myocardial infarction: the Trent study. Br Med J (Clin Res Ed) (1986) 2.55
Natural populations of Trypanosoma cruzi, the agent of Chagas disease, have a complex multiclonal structure. Proc Natl Acad Sci U S A (1986) 2.48
PRAK, a novel protein kinase regulated by the p38 MAP kinase. EMBO J (1998) 2.44
Pathways of activation of the Epstein-Barr virus productive cycle. J Virol (1991) 2.42
Human papillomavirus type 16 sequence variation in cervical cancers: a worldwide perspective. J Virol (1997) 2.40
Human polyomavirus infection in renal allograft recipients. Br Med J (1973) 2.32
Novel nuclear antigens recognized by human sera in lymphocytes latently infected by Epstein-Barr virus. Virology (1987) 2.32
Recombinant interleukin-2 directly augments the cytotoxicity of human monocytes. Nature (1987) 2.31
Carcinoma of the cervix and tobacco smoking: collaborative reanalysis of individual data on 13,541 women with carcinoma of the cervix and 23,017 women without carcinoma of the cervix from 23 epidemiological studies. Int J Cancer (2006) 2.27
The BZLF1 protein of EBV has a coiled coil dimerisation domain without a heptad leucine repeat but with homology to the C/EBP leucine zipper. Oncogene (1991) 2.25
Cyclic oscillations of basal plasma glucose and insulin concentrations in human beings. N Engl J Med (1979) 2.25
Asymmetric replication in vitro from a human sequence element is dependent on adeno-associated virus Rep protein. J Virol (1995) 2.23
Interferon action: two distinct pathways for inhibition of protein synthesis by double-stranded RNA. Proc Natl Acad Sci U S A (1978) 2.22
Price and consumption of cigarettes: a case for intervention? Br J Prev Soc Med (1974) 2.22
Occupational, domestic and environmental mesothelioma risks in the British population: a case-control study. Br J Cancer (2009) 2.18
Site-specific integration by adeno-associated virus. Proc Natl Acad Sci U S A (1996) 2.12
Insulin deficiency and insulin resistance interaction in diabetes: estimation of their relative contribution by feedback analysis from basal plasma insulin and glucose concentrations. Metabolism (1979) 2.07
Over-diagnosis of hydatidiform mole in early tubal ectopic pregnancy. Histopathology (2001) 2.06
Prospective study of cancer in patients with hypogammaglobulinaemia. Lancet (1985) 2.03
The hygiene standard for chrysotile asbestos. Lancet (1978) 2.02
HPV testing in routine cervical screening: cross sectional data from the ARTISTIC trial. Br J Cancer (2006) 1.99
Guidelines for simple, sensitive significance tests for carcinogenic effects in long-term animal experiments. IARC Monogr Eval Carcinog Risk Chem Hum Suppl (1980) 1.99
Homologous upstream sequences near Epstein-Barr virus promoters. Proc Natl Acad Sci U S A (1983) 1.98
Structure and function of the Epstein-Barr virus BZLF1 protein. J Virol (1990) 1.97
Spatial and temporal operation of the Scotia Sea ecosystem: a review of large-scale links in a krill centred food web. Philos Trans R Soc Lond B Biol Sci (2007) 1.95
Sequence analysis of Raji Epstein-Barr virus DNA. Virology (1988) 1.95
Retracted Relation between infection with a subtype of HPV16 and cervical neoplasia. Lancet (1989) 1.94
A prospective study of human polyomavirus infection in pregnancy. J Infect Dis (1980) 1.92
National study of colorectal cancer genetics. Br J Cancer (2007) 1.92
Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies. J Med Genet (2005) 1.91
Regulation of an essential innate immune response by the p50 subunit of NF-kappaB. J Clin Invest (1998) 1.89
Phosphoenolpyruvate carboxylase from the crassulacean plant Bryophyllum fedtschenkoi Hamet et Perrier. Purification, molecular and kinetic properties. Biochem J (1978) 1.86
Immunologically defined subclasses of acute lymphoblastic leukaemia in children: their relationship to presentation features and prognosis. Br J Haematol (1981) 1.83
Relationship of mortality to measures of environmental asbestos pollution in an asbestos textile factory. Ann Occup Hyg (1985) 1.83
An overview of prognostic factors in small cell lung cancer. A report from the Subcommittee for the Management of Lung Cancer of the United Kingdom Coordinating Committee on Cancer Research. Br J Cancer (1990) 1.83
Sequence and transcription of Raji Epstein-Barr virus DNA spanning the B95-8 deletion region. Virology (1990) 1.78
Prevalence of type-specific HPV infection by age and grade of cervical cytology: data from the ARTISTIC trial. Br J Cancer (2008) 1.77
Completeness of cancer registration: a new method for routine use. Br J Cancer (2000) 1.75
Pharmacokinetics and dosage recommendations for an oseltamivir oral suspension for the treatment of influenza in children. Paediatr Drugs (2001) 1.74
Sexual behaviour and smoking as determinants of cervical HPV infection and of CIN3 among those infected: a case-control study nested within the Manchester cohort. Br J Cancer (2000) 1.74
Results of Medical Research Council Childhood Leukaemia Trial UKALL VIII (report to the Medical Research Council on behalf of the Working Party on Leukaemia in Childhood). Br J Haematol (1991) 1.70
Interferon, double-stranded RNA and RNA degradation. Fractionation of the endonucleaseINT system into two macromolecular components; role of a small molecule in nuclease activation. Biochem Biophys Res Commun (1978) 1.70
Association of innate immune activation with latent Epstein-Barr virus in active MS lesions. Neurology (2011) 1.70
A mortality study among workers in an English asbestos factory. Br J Ind Med (1977) 1.69
HIV testing on all pregnant women. Lancet (1987) 1.66
Cytokine induction of monocyte chemoattractant protein-1 gene expression in human endothelial cells depends on the cooperative action of NF-kappa B and AP-1. Eur J Immunol (1997) 1.66
An update of cancer mortality among chrysotile asbestos miners in Balangero, northern Italy. Br J Ind Med (1990) 1.65
Intratype variation in 12 human papillomavirus types: a worldwide perspective. J Virol (1996) 1.65
Histone acetylation and reactivation of Epstein-Barr virus from latency. J Virol (2000) 1.64
That the effects of smoking should be measured in pack-years: misconceptions 4. Br J Cancer (2012) 1.63
The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2. Clin Cancer Res (2000) 1.62
Mapping of the gene coding for Epstein-Barr virus-determined nuclear antigen EBNA3 and its transient overexpression in a human cell line by using an adenovirus expression vector. J Virol (1987) 1.61